title: Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy.
abstract: In the present study we developed doxorubicin-loaded solid lipid nanoparticles (SLN-Dox) using biocompatible compounds, assessed the in vitro hemolytic effect, and examined their in vivo effects on drug retention and apoptosis intensity in P-glycoprotein-overexpressing MCF-7/ADR cells, a representative Dox-resistant breast cancer cell line. Our SLNs did not show hemolytic activity in human erythrocytes. In comparison with Dox, SLN-Dox efficiently enhanced apoptotic cell death through the higher accumulation of Dox in MCF-7/ADR cells. Therefore, SLN-Dox have potential to serve as a useful therapeutic approach to overcome the chemoresistance of adriamycin-resistant breast cancer.
  
  
  BACKGROUND
  Doxorubicin loaded solid lipid nanoparticles (SLN-Dox) were studied in a cell line representative of doxorubicin resistant breast cancer. The nanoparticles did not show hemolytic activity; furthermore, they efficiently enhanced apoptotic cell death through higher accumulation of doxorubicin in cancer cells. This approach may be viable in overcoming the chemoresistance of adriamycin resistant breast cancer.
authors.affiliation: BK21 Project Team, College of Pharmacy, Chosun University, Gwangju, South Korea.
authors.forename: Keon Wook
authors.initials: KW
authors.lastname: Kang
authors.forename: Myung-Kwan
authors.initials: MK
authors.lastname: Chun
authors.forename: Ok
authors.initials: O
authors.lastname: Kim
authors.forename: Robhash Kusam
authors.initials: RK
authors.lastname: Subedi
authors.forename: Sang-Gun
authors.initials: SG
authors.lastname: Ahn
authors.forename: Jung-Hoon
authors.initials: JH
authors.lastname: Yoon
authors.forename: Hoo-Kyun
authors.initials: HK
authors.lastname: Choi
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D018432:Drug Resistance, Multiple; D008055:Lipids / Q000737:chemistry*; D051379:Mice; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry*
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008055:Lipids; D004317:Doxorubicin